Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus DERMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus DERMACORT.
AMCINONIDE vs DERMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Apply a thin film to affected area twice daily (every 12 hours) for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 2-3 hours for hydrocortisone, the active component. Due to its short half-life, it requires multiple daily doses for sustained effect.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Primarily hepatic metabolism; metabolites are excreted renally (~75% as glucuronide and sulfate conjugates) and fecally (~25%). Less than 5% of the dose is excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."